APLS, NasdaqGS

Apellis Pharmaceuticals, Inc. (APLS)

Price (as of September 15)

66.67USD

Correlations

The correlation describes the statistical relationship between the value of two assets over time. Use this relationship to bet against an asset without shorting it or diversify your portfolio more effectively. Learn how you can use correlations to your advantage.

Lowest within Industry

Symbol Correlation

TCBPW

TC Biopharm (Holdings) Plc

-0.13

RNXT

RenovoRx, Inc.

-0.12

XLO

Xilio Therapeutics, Inc.

-0.12

EXAI

Exscientia plc

-0.11

THRX

Theseus Pharmaceuticals, Inc.

-0.11

ROIV

Roivant Sciences Ltd.

-0.11

DRMA

Dermata Therapeutics, Inc.

-0.1

RLYB

Rallybio Corporation

-0.1

GLS

Gelesis Holdings, Inc.

-0.1

CRVS

Corvus Pharmaceuticals, Inc.

-0.09

Show more

Highest within Industry

Symbol Correlation

GRTX

Galera Therapeutics, Inc.

0.37

ALLO

Allogene Therapeutics, Inc.

0.28

ALNY

Alnylam Pharmaceuticals, Inc.

0.28

APLT

Applied Therapeutics, Inc.

0.26

ALVR

AlloVir, Inc.

0.25

AMLX

Amylyx Pharmaceuticals, Inc.

0.22

AMTI

Applied Molecular Transport Inc.

0.21

MIRO

Miromatrix Medical Inc.

0.2

ANNX

Annexon, Inc.

0.2

APTO

Aptose Biosciences Inc.

0.2

Show more

Profile

Sector:
Healthcare
Industry:
Biotechnology

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company’s lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases. It also develops EMPAVELI (systemic pegcetacoplan) for the treatment of cold agglutinin disease (CAD), and hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) in hematology; C3 glomerulopathy (C3G), and immune complex membranoproliferative glomerulonephritis (IC-MPGN) in nephrology; and amyotrophic lateral sclerosis (ALS) in neurology. In addition, the company develops APL-2006, a bispecific C3 and VEGF inhibitor for treating complement-mediated disorders; APL-1030, a C3 inhibitor for the treatment of multiple neurodegenerative diseases; and the combination of EMPAVELI and a small interfering RNA, or siRNA for reducing the production of C3 proteins by the liver. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) to co-develop pegcetacoplan; and a research collaboration with Beam Therapeutics Inc. focused on the use of Beam’s base editing technology to discover new treatments for complement-driven diseases. Apellis Pharmaceuticals, Inc. was incorporated in 2009 and is based in Waltham, Massachusetts.